| Code | CSB-RA001950MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to reference antibody AA001, targeting amyloid precursor protein (APP). APP is a type I transmembrane glycoprotein that plays crucial roles in neuronal development, synaptic plasticity, and cell adhesion. Sequential proteolytic processing of APP by β-secretase and γ-secretase generates amyloid-beta (Aβ) peptides, which aggregate to form the characteristic amyloid plaques found in Alzheimer's disease. Dysregulation of APP processing and metabolism is central to the pathogenesis of Alzheimer's disease and other neurodegenerative disorders, making it a critical target for investigating disease mechanisms and potential therapeutic interventions.
As a biosimilar to AA001, this antibody provides researchers with a reliable tool for studying APP expression, localization, and processing in various experimental models. It is particularly valuable for investigations into amyloid-beta generation, APP trafficking, and the molecular mechanisms underlying neurodegeneration. This antibody supports diverse research applications in neuroscience, cell biology, and drug discovery programs focused on Alzheimer's disease and related conditions.
There are currently no reviews for this product.